NEW YORK (GenomeWeb) – San Francisco-based Linkage Biosciences today announced the launch of a wholly-owned European subsidiary based in Geneva.
The move is in response to global demand for LinkSeq molecular tissue typing technology, the firm said in a statement. The real-time PCR-based human leukocyte antigen testing technology covers 12,000 alleles in a single test, the firm said.
"Our new Swiss operations will extend our global reach and provide superior support and service to customers across the region," Linkage Biosciences' CEO Zachary Antovich said in a statement.